<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120535</url>
  </required_header>
  <id_info>
    <org_study_id>Crux04</org_study_id>
    <nct_id>NCT01120535</nct_id>
  </id_info>
  <brief_title>Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter 4</brief_title>
  <acronym>RETRIEVE 4</acronym>
  <official_title>Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 4 (RETRIEVE 4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crux Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crux Biomedical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the Crux Vena Cava Filter System is safe and&#xD;
      effective in preventing pulmonary embolism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>6 Months</time_frame>
    <description>Clinical Success is a composite endpoint consisting of technical success with freedom from pulmonary embolism, filter migration and device related events requiring intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of complications related to vena cava filter use.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Crux Vena Cava Filter System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects at risk for Pulmonary Embolism</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Inferior Vena Cava Filter</intervention_name>
    <description>Inplant of filter in inferior vena cava.</description>
    <arm_group_label>Crux Vena Cava Filter System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has a permanent or temporary risk of Pulmonary Embolism.&#xD;
&#xD;
          -  Patient must provide informed consent At least one of the following conditions -&#xD;
&#xD;
          -  Proven PE&#xD;
&#xD;
          -  Recurrent PE despite adequate&#xD;
&#xD;
          -  Contraindication to anticoagulation&#xD;
&#xD;
          -  Inability to achieve/maintain therapeutic anticoagulation&#xD;
&#xD;
          -  Iliocaval DVT&#xD;
&#xD;
          -  Large, free-floating proximal DVT&#xD;
&#xD;
          -  Massive PE treated with thrombolysis/thrombectomy&#xD;
&#xD;
          -  Chronic PE treated with thrombectomy&#xD;
&#xD;
          -  Protection during thrombolysis for iliocaval DVT&#xD;
&#xD;
          -  PE with limited cardiopulmonary reserve&#xD;
&#xD;
          -  Poor compliance with anticoagulation medication&#xD;
&#xD;
          -  High risk of injury worsening on anticoagulation&#xD;
&#xD;
          -  Multi-trauma patient with high risk of PE&#xD;
&#xD;
          -  Surgical patients at high risk of PE&#xD;
&#xD;
          -  Medical condition with high risk of PE Patients with a documented vena cava diameter&#xD;
             of 17-28mm Patient has IVC anatomy suitable for infra-renal placement Patient is&#xD;
             willing to be available for the appropriate follow up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years old&#xD;
&#xD;
          -  Patient has any one of the following conditions:&#xD;
&#xD;
               -  Renal vein thrombosis&#xD;
&#xD;
               -  IVC thrombosis extending to the renal veins&#xD;
&#xD;
               -  Duplicate IVC&#xD;
&#xD;
               -  Gonadal vein thrombosis&#xD;
&#xD;
               -  Requires supra-renal placement&#xD;
&#xD;
          -  Vena cava diameter of 17-28mm&#xD;
&#xD;
          -  Uncontrolled infectious disease&#xD;
&#xD;
          -  Risk of aseptic PE&#xD;
&#xD;
          -  Uncontrolled coagulopathy&#xD;
&#xD;
          -  Existing inferior vena cava filter implant&#xD;
&#xD;
          -  Life expectancy less than 6 months&#xD;
&#xD;
          -  Pregnant or planning a pregnancy in the next 6 months&#xD;
&#xD;
          -  Condition that inhibits radiographic visualization of the IVC&#xD;
&#xD;
          -  Known allergy or intolerance to polytetrafluoroethylene (PTFE) or Nitinol&#xD;
&#xD;
          -  Known hypersensitivity to contract which cannot be pretreated&#xD;
&#xD;
          -  Access vessels preclude same insertion of delivery system&#xD;
&#xD;
          -  Participation in another drug or device trial&#xD;
&#xD;
          -  Unable or unwilling to cooperate with study procedures or required follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal Brisbane Womens Hospital</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23622035</url>
    <description>Smouse H, Mendes R, Bosiers M et al. The RETRIEVE Trial: Safety and Effectiveness of the Retrieval Crux Vena Cava Filter. JVIR 2013; 24:609-621.</description>
  </link>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2010</study_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vena Cava</keyword>
  <keyword>Vena Cava Filter</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>Risk of Pulmonary Embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

